Targeted therapy decreases progression rate in thyroid cancer
Saturday, September 18, 2010 - 06:42
in Health & Medicine
The drug pazopanib may help revolutionize the care of patients with metastatic, rapidly progressive differentiated thyroid cancers, say researchers at Mayo Clinic who are publishing findings of a phase II clinical trial in The Lancet Oncology.